| INTRODUCTION
Metastatic prostate tumors secrete factors that precondition, not only the tumor stroma but also the remaining benign parts of the prostate, in ways that facilitate subsequent tumor growth and spread. [1] [2] [3] [4] [5] If metastatic prostate tumors secrete factors that also prepare regional lymph nodes (LNs) for metastatic growth is only limitedly explored. Such pre-metastatic niches have been shown to exist in various organs, including regional LNs, in other tumor types. [6] [7] [8] [9] [10] [11] For example, tumors with high metastatic capacity suppress anti-tumor immune responses in LNs prior to metastatic colonization. 9, [11] [12] [13] [14] [15] [16] [17] In tumor-free regional LNs from prostate cancer patients, an increased number of cells expressing VEGFR1, 18, 19 and IL-30 20 have been shown to predict subsequent metastatic disease after radical prostatectomy. Furthermore, tumor-free LNs from prostate cancer patients contained more CD68 + and pSTAT3 + myeloid cells than LNs form individuals without prostate cancer. 13 LNs containing prostate cancer metastases showed signs of immunosuppression and were smaller than normal, and these responses probably occurred prior to the arrival of metastatic cells. 21 Collectively, this suggests that examination of regional LNs could give information on tumor aggressiveness that could potentially aid in the choice of therapy.
We recently compared the global gene expression in tumor-draining
LNs from rats implanted with two different orthotopic tumors − the poorly metastatic AT1-tumors and the highly metastatic MatLyLu (MLL)-tumors. 5 The gene expression profile in pre-metastatic MLL-LNs was associated with decreased antigen presentation, increased immunosuppression, and a reduced density of T lymphocytes. 5, 22 One gene with lower expression in pre-metastatic MLL-LNs was Cd169 (Siglec1) (fold change −1.7, P = 0.01 vs LNs from treatment naive animals, and fold change −1.5, P = 0.08 vs AT1-LNs). 5 CD169 is normally expressed by subsets of macrophages in secondary lymphoid organs, for example, by subcapsular-and medullary sinus macrophages in LNs. 23 By capturing and presenting tumor-derived antigens, subcapsular sinus macrophages promote anti-tumor immune responses and could in this way retard tumor growth and spread. [23] [24] [25] [26] [27] A high density of CD169 + macrophages in tumor-free regional LNs was associated with a favorable prognosis in melanoma, colorectal-, and endometrial cancer. 24, [27] [28] [29] The aim of this study was to examine CD169 expression in premetastatic LNs in more detail, both in the animal model and in prostate
cancer patients. We demonstrate that rats implanted with highly metastatic prostate tumors have reduced numbers of CD169 + macrophages in tumor-draining LNs compared with rats implanted with less metastatic tumors. In prostate cancer patients, reduction of CD169 expression in regional LNs was associated with an increased risk of prostate cancer death in patients treated with prostatectomy.
| MATERIALS AND METHODS

| Animals
The local ethical committee for animal research approved all of the animal work (permit number A42-15). The methods used for the animal experiments in this study have previously been used, and described. 22 Briefly, poorly metastatic AT1-and highly metastatic MLL-Dunning rat prostate tumor cells 30 were purchased from European Collection of Cell Cultures (ECACC, Salisbury, UK. MLL #94101454, AT1 #94101449) and were cultured as previously described. 5 Immunocompetent and syngeneic adult Copenhagen rats (Charles River, Sulzfeld, Germany)
were used in all experiments. Animals were anesthetized and 2 × 10 4 AT1 cells, or 1 × 10 3 MLL cells (suspended in 10 μL RPMI 1640) were carefully injected into one of the ventral prostate lobes as earlier described. 5 Rats were sacrificed 3 (n = 8/treatment), and 10 days (n = 8/ treatment) after tumor cell injection. The tumor-containing prostates and the tumor-draining regional LNs were removed, weighed, frozen in liquid nitrogen, and stored in −80°C. Tissues from treatment-naïve rats (n = 8)
and from vehicle-injected rats (n = 10) were used as controls.
| Patients
From 
| Immunohistochemistry
Four micron thick cryosections from rat regional LNs were fixed in formalin and immunostained using a mouse monoclonal anti-rat CD169 antibody (diluted 1:100, #LS-C124538, LSBio, Seattle, WA). The immunoreaction was detected using Mouse-on-rat HRP-polymer (#MRT621, Biocare Pacheco, CA) and visualized using diaminobenzidine tissue from all patients were sectioned, stained and scored twice, and the second score was compared to the first.
| Statistical analysis
Fisher's exact test was used to compare CD169 staining score in relation to disease outcome in different patient subgroups. Possible The CD169 score from the animal experiment is presented as mean ± SD, and Mann-Whitney U test was used when comparing groups.
All statistics was computed in SPSS software (SPSS statistics 23, IBM, Armonk, NY), and a P-value <0.05 was considered to be significant.
| RESULTS
3.1 | Growth of metastatic PC in rats in relation to CD169 + macrophages in pre-metastatic lymph nodes
To examine if the volume density of CD169 + macrophages were affected in regional LNs prior to metastasis we used a rat prostate In most patients, CD169 + macrophages were observed in the subcapsular-and medullary sinuses of the LNs (Figure 2 ). However, in 27 patients the CD169 staining was markedly reduced or absent ( Figure 2 ). In the group with low CD169 score, eight patients (30%) died due to prostate cancer, while in the group with high CD169 score, only three patients (3.7%) died of prostate cancer (P = 0.001, Table 1 ).
We therefore further explored the CD169 score and other factors known to be associated with prostate cancer outcome ( Table 1) . High PSA nadir, PSA-relapse, high Gleason score, and high ISUP Gleason grade group was significantly related to prostate cancer death (Table 1 ).
In the Kaplan-Meier survival analysis, patients with low CD169 score had a significantly shorter survival time than patients with high To further assess the significance of CD169 score compared to the other clinically established markers for prognosis, uni-and multivariable Cox regression analysis was performed. In univariable analysis, low CD169 score, Gleason score, high ISUP Gleason grade group, high PSA nadir, and PSA-relapse, were all related to increased risk of prostate cancer death (Table 2 ). In multivariable stepwise elimination analysis, only CD169 score and PSA-relapse remained significantly associated with an increased risk of dying from prostate cancer (Table 2 ).
| CD169 expression in relation to PSA-relapse
We tested if the CD169 score was associated to PSA-relapse and compared the result with established prognostic markers of PSArelapse (Table 3 ). In line with multiple previous studies, preoperative PSA, PSA nadir, tumor Gleason score, ISUP Gleason grade group, tumor stage, and positive surgical margins, were all related to the risk of PSA-relapse, but CD169 score was not (Table 3) .
As CD169 expression appeared more strongly related to prostate cancer death than to PSA-relapse, we grouped patient with PSArelapse into those that died from prostate cancer and those who did not (Table 4 ). In patients with PSA-relapse, a low CD169 score was associated to an increased risk of dying from prostate cancer compared to those with a high CD169 score (Table 4) . Interestingly, in patients with PSA-relapse, only CD169 score was related to prostate cancer death.
| Robustness of CD169 staining and scoring
All lymph nodes were sectioned, stained, and scored twice without knowledge of the previous result. In total, the scoring differed in nine out of 110 cases. Eight low cases were re-classified as high and one case initially scored high was re-scored as low. Among the 11 patients dying from prostate cancer, one case with low score was rescored as high. This suggests that the scoring was relatively robust 
| DISCUSSION
The principal observation in this paper is that reduced CD169 expression in tumor-draining LNs is associated to aggressive prostate cancer. Highly metastatic rat prostate tumors induced down-regulation Step 1 CD169 score** low vs high 4. Step 7
CD169 score** low vs high 4. | 1473 of CD169 expression in pre-metastatic regional LNs. In prostate cancer patients, a low number of CD169 + macrophages in metastasis-free regional LNs was significantly associated to an increased risk of prostate cancer associated death.
Metastatic cancers suppress anti-tumor immune responses in regional LNs prior to metastasis. 8, [11] [12] [13] 15, 17, 24 In line with this, the global gene expression in regional LNs from rats carrying highly metastatic MLL-prostate tumors indicated increased immunosuppression and reduced antigen presentation prior to metastasis. 5 Cd169
(Siglec1) mRNA expression was shown to be decreased in highly metastatic MLL-versus poorly metastatic AT1-LNs. 5 Consistent with the previous study, we now demonstrate that this is accompanied by a reduced number of CD169 + macrophages in MLL-LNs.
In lymph nodes, CD169 is normally expressed by macrophages in the subcapsular-and medullary sinuses. 23 One function of the subcapsular sinus-macrophages is to capture lymph borne particles, including tumor-derived antigens and exosomes. 25, 26, 34 Antigens sampled by the CD169 + macrophages are presented to effector cells like T-cells and NK-cells, which migrate to the tumor where they promote an anti-tumor immune response. 35 In breast cancer, the density of CD169 + cells in regional LNs correlated with clinical stage, and also with numbers of cytotoxic CD8 + T cells in high grade tumors, but was not associated to cancer specific survival. 36 In our experimental model, we found that rats carrying poorly metastatic AT1-tumors had a higher density of CD169 + macrophages in the tumor-draining LNs and in a previous study we also found a higher amount of tumor-infiltrating CD3 + T-cells, 5 compared with rats carrying highly metastatic MLL-tumors. Similarly, high levels of CD169 + cells in regional LNs correlated with high numbers of cytotoxic CD8 + T-cells in melanoma, colon, and endometrial tumors, and this was associated with a favorable clinical outcome. 24, [27] [28] [29] Our observation that highly metastatic rat prostate cancers involved. 5 Tumor-derived exosomes is one key factor adapting premetastatic sites to the subsequent arrival and growth of neoplastic cells. 8, 11, 15, 38 Effects of tumor-derived exosomes on regional LNs have not been examined in our model system. However, MLL-derived exosomes injected into the prostate precondition it for accelerated growth of low-malignant prostate cancer cells implanted 3 days later. 3 It is likely that MLL-exosomes also could influence the tumor-draining LNs in a similar tumor-promoting way.
One limitation of this study is the low number of patients examined. This makes our study underpowered to prove a robust relation between low CD169 expression and increased risk of prostate cancer death. Nevertheless, our data suggest that CD169 expression in pre-metastatic regional LNs could be used, together with other markers, to evaluate prostate tumor aggressiveness. This however needs to be validated in larger studies using standardized staining and quantification methods. Evaluation of CD169 expression could be done either prior to choice of primary therapy, or to determine the need and choice of additional therapies.
| CONCLUSIONS
In animals, and in patients with localized prostate cancer, reduced density of CD169 + sinus macrophages in pre-metastatic regional LNs appear to be associated with subsequent metastatic colonization and a poor outcome.
